Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease
Authors
Keywords
-
Journal
KOREAN JOURNAL OF INTERNAL MEDICINE
Volume 35, Issue 2, Pages 276-283
Publisher
Korean Association of Internal Medicine
Online
2020-02-28
DOI
10.3904/kjim.2020.035
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Management of COPD in Asia: A position statement of the Asian Pacific Society of Respirology
- (2019) Chin Kook Rhee et al. RESPIROLOGY
- The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients
- (2019) Simon Lea et al. CYTOKINE
- Determinants of Response to Roflumilast in Severe COPD: Pooled Analysis of Two Randomized Trials
- (2018) Fernando J. Martinez et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
- (2018) Henrik Watz et al. International Journal of Chronic Obstructive Pulmonary Disease
- The short term bronchodilator effects of the dual PDE3 and PDE4 inhibitor RPL554 in COPD
- (2018) Dave Singh et al. EUROPEAN RESPIRATORY JOURNAL
- Impact of BMI on exacerbation and medical care expenses in subjects with mild to moderate airflow obstruction
- (2018) Yong Suk Jo et al. International Journal of Chronic Obstructive Pulmonary Disease
- Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial
- (2018) Klaus F Rabe et al. Lancet Respiratory Medicine
- Direct Inhibitory Effect of the Phosphodiesterase-4 Inhibitor, Roflumilast, on Neutrophil Migration in COPD
- (2018) Amy E Dunne et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Effect of roflumilast in patients with severe COPD and a history of hospitalisation
- (2017) Klaus F. Rabe et al. EUROPEAN RESPIRATORY JOURNAL
- Airway Mucin Concentration as a Marker of Chronic Bronchitis
- (2017) Mehmet Kesimer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients
- (2017) Jeong Uk Lim et al. International Journal of Chronic Obstructive Pulmonary Disease
- Risk factors for the discontinuation of roflumilast in patients with chronic obstructive pulmonary disease
- (2017) Kyung Hoon Kim et al. International Journal of Chronic Obstructive Pulmonary Disease
- Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND). A Randomized Clinical Trial
- (2016) Fernando J. Martinez et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Effect of roflumilast on airway remodelling in a murine model of chronic asthma
- (2016) S. W. Kim et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Roflumilast: a review of its use in the treatment of COPD
- (2016) Jadwiga Wedzicha et al. International Journal of Chronic Obstructive Pulmonary Disease
- A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease
- (2015) J. Michael Wells et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Roflumilast: A Review in COPD
- (2015) Karly P. Garnock-Jones DRUGS
- Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease
- (2014) Javier Milara et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis
- (2013) James A. Lambert et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD
- (2013) William B. White et al. CHEST
- How Phosphodiesterase 4 Inhibitors Work in Patients with Chronic Obstructive Pulmonary Disease of the Severe, Bronchitic, Frequent Exacerbator Phenotype
- (2013) Mark A. Giembycz et al. CLINICS IN CHEST MEDICINE
- Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus
- (2012) E. F. M. Wouters et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
- (2012) Alvar Agustí et al. PLoS One
- Mechanisms and resistance in glucocorticoid control of inflammation
- (2010) Peter J. Barnes JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release
- (2009) WK Ong et al. BRITISH JOURNAL OF PHARMACOLOGY
- Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
- (2009) Peter MA Calverley et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started